MEOBF News and Press, Mesoblast Ltd Ord From 10/07/25

2025-10-07 14:57:04 ET Introduction Mesoblast’s stock ( MESO ) is up 70% since my rating upgrade from Sell to Hold in July 2025.... Read the full article on Seeking Alpha For further details see: Mesoblast: Back Pain And Heart Failure Remain Option Val...

2025-10-07 00:34:53 ET More on Mesoblast Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript Mesoblast Limited 2025 Q4 - Results - Earnings Call Presentation Seeking Alpha’s Quant Rating on Mesoblast Historical earnings data for Mesoblast ...

NEW YORK, Oct. 06, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced gross revenue of US$21.9 million on Ryoncil ® (remestemcel-L-rknd) sales for the quarter ended September 30, 202...

NEW YORK, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced that a specific Healthcare Common Procedure Coding System (HCPCS) J-Code assigned to Ryoncil ® (remestemcel-L-rk...

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today reiterated that its allogeneic cell therapy products are manufactured from U.S. donors in the U.S. and designated as U.S. origin p...

NEW YORK, Sept. 14, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, announced that the successful commercial launch of Ryoncil ® (remestemcel-L-rknd), the only mesenchymal stromal cell (MSC) prod...

2025-09-04 01:34:02 ET More on Mesoblast Mesoblast Limited (MESO) Q4 2025 Earnings Call Transcript Mesoblast Limited 2025 Q4 - Results - Earnings Call Presentation Mesoblast: A Cautionary Hold On Regenerative Medicine's Risky Edge (Upgrade) Mesoblast, FDA agr...

NEW YORK, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced it has entered into convertible note subscription agreements with SurgCenter principals and existing Mesoblast sharehold...

2025-08-29 12:27:54 ET Mesoblast Limited (MESO) Q4 2025 Earnings Conference Call August 28, 2025 06:30 PM ET Company Participants Andrew Chaponnel - Interim Chief Finance Officer Marcelo Santoro - Chief Commercial Officer Silviu Itescu - Founder, CEO, MD, Chairma...

NEW YORK, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Mesoblast Limited (ASX:MSB; Nasdaq:MESO), global leader in allogeneic cellular medicines for inflammatory diseases, today provided financial results and an operational update for the period ended June 30, 2025. Mesoblast Chief Executive Dr. Silviu I...